How coronavirus disease 2019 entered Africa and the Middle East: a case study from Egypt

Nourhan M. Khattaba, Sten H. Vermund, and Yifei Hu

Department of Child and Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, No.10 You’amenwai Xitoutiao, Fengtai District, Beijing 100069, China; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, and Department of Pediatrics, Yale School of Medicine, P.O. Box 208034, New Haven, CT 06520-8034, USA

*Corresponding author: Tel: +86-10-83911747; E-mail: huyifei@yahoo.com; huyifei@ccmu.edu.cn

Received 16 April 2020; revised 9 July 2020; editorial decision 19 July 2020; accepted 21 July 2020

Background: We report the first person with SARS-CoV-2 in Egypt.

Methods: We interviewed the index case and contacts.

Results: The 36-year old man was healthy when he traveled on business to Wuhan, China in January 2020. Upon his return to Cairo, he became ill, went to work, and subsequent autochthonous viral spread occurred.

Conclusion: We linked SARS-CoV-2 importation to global business travel. The extent to which physical distancing, hand/face/surface hygiene, mask use, viral testing/contact tracing, restricted travel, small gatherings, and/or stay-in-residence mandates will be implemented and limit further spread in the Middle East and North Africa remains to be seen.

Keywords: COVID-19, Egypt, SARS-CoV-2, epidemiology, transmission, outbreak

Introduction

We investigated what we believe to be the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case to emerge in Egypt, a crossroads of the Middle East and Africa. Our presumptive case and confirmed cases represent among the earliest regional cases outside of Iran. This case study illuminates global transmission dynamics and suggests how quickly infection can spread, even between countries that have relatively few non-stop flights between them.

Earliest cases in Egypt

A healthy 27-year-old Egyptian woman, Ms A, worked as a translator for two Chinese managers of a Japan-based designer brand whose manufacturing capacity is in China. The first manager was a 54-year-old female, Ms B, with business duties in multiple African countries. The second manager was a 36-year-old male, Mr C, with responsibility for the Egyptian market. Both managers and Ms A travelled on business to China from 5 to 18 January 2020 (Figure 1). Ms A and Ms B were in Guangzhou while Mr C went to Wuhan. The three travellers reunited on 18 January in Guangzhou for their return trip to Egypt. On 19 January, Mr C went to his workplace in Cairo with severe influenza-like symptoms, including fever and cough. Despite his obvious illness, Mr C worked in the office the whole day, sharing a workspace with three employees, including Ms A and a third Chinese manager, Mr D, age 37 years. On 20 January 20, Mr C was still ill with respiratory symptoms and fever and he isolated himself, given his history of recent travel to Wuhan. Ms B shared the same dwelling as Mr C and Mr D, but all three occupied different rooms. Ms B secured a service to disinfect the home and change the furniture, given the illness of Mr C. On 24 January 24, Ms B developed a fever, cough and sore throat, suggesting a respiratory illness. Mr D then fell ill with respiratory disease on an unspecified date. Ms A remained asymptomatic. In late January there were no coronavirus disease 2019 (COVID-19) diagnostic tests available in Egypt. Ms B and Mr C returned to Guangzhou on 4 February 2020. Mr C recovered completely but Ms B suffered from persistent cough and was confirmed as a COVID-19 case on 11 February based on a reverse transcription polymerase chain reaction test in China. It seems likely that both Mr C and Ms B were the first COVID-19 cases in Egypt, although they were never registered in Egypt as cases, given their return to China.

Also on 11 February, the Cairo office was informed by their China office colleagues that all exposed employees should be tested for SARS-CoV-2. Mr D, Ms A and about 22 other employees received complete blood counts, chest X-rays and nasal and
Figure 1. Timeline of early SARS-CoV-2 transmission in Egypt, 2020.

Discussion

These cases illustrate the global dynamics of the coronavirus pandemic, in particular how modern business and air travel can transmit viral pathogens to far-distant venues. Ms B did not travel to Wuhan, but was presumably infected by Mr C who did travel there (Mr C was a presumptive case, but remains unconfirmed). Mr D was exposed and infected in the shared dwelling or workplace but was asymptomatic. The heterogeneity of risk is highlighted by Ms A, who was exposed for prolonged periods to Mr C and Ms B during travel and at the workplace, but was never infected, as well as three other employees, also exposed for many hours in the workplace, but never infected (Figure 1).

Although the reporting of early symptomatic cases was urged by the Egyptian Ministry of Health from the very start of the pandemic, unidentified cases—either symptomatic or asymptomatic—contributed substantially to further SARS-CoV-2 spread nationwide and abroad. At a time of no local
testing capacity, COVID-19 cases were imported to Egypt from China through global air travel. Eventually the COVID-19 pandemic led to cessation of most international flights between afflicted countries, although it was too late to prevent global viral spread. Egypt, Algeria and South Africa represented the highest importation risk of COVID-19 from China to Africa according to one modelling study of global travel patterns. Egypt stopped all flights in late March through 1 July and applied a night-time curfew to limit the spread in social groups. Despite early, aggressive and restrictive control measures, Egypt has experienced a transition from its first few cases to a severe upward spike with cumulative cases of >70 000 (as of July 2020) after mass gatherings for festivals and loosened enforcement of physical distancing. More cases are emerging in Africa and the Middle East and these will burden underresourced hospitals and health systems, representing a special risk for the elderly and persons with pre-existing medical conditions. The global community was not prepared for a pandemic respiratory disease threat on the magnitude of COVID-19, or novel influenza strains, least of all low- and middle-income countries.

Authors’ contributions: YH and SHV conceptualized the study. NMK carried out the interviews and investigation. NMK and YH drafted the manuscript. SHV and YH interpreted the findings and edited and revised the manuscript. All authors had final approval of the submitted and published versions.

Acknowledgements: None.

Funding: YH is supported in part by the National Natural Science Foundation of China (81673232) and Beijing Natural Science Foundation (7202009). SHV is supported in part by the National Institutes of Health (grant P30MH062294). The sponsors had no role in the study design; collection, analysis and interpretation of data; writing of the report or the decision to submit the paper for publication.

Competing interests: None.

Ethics approval: The study was approved by the Capital Medical University Ethics Review Board (2020SY004).

References
1 Barry M, Al Amri M, Memish ZA. COVID-19 in the shadows of MERS-CoV in the Kingdom of Saudi Arabia. J Epidemiol Glob Health. 2020;10(1):1–3.
2 Adepoju P. Nigeria responds to COVID-19; first case detected in sub-Saharan Africa. Nat Med. 2020;26(4):444–8.
3 Kapata N, Ihekwezu C, Ntoumi F, et al. Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future. Int J Infect Dis. 2020;93:233–6.
4 Nkengasong JN, Mankoula W. Looming threat of COVID-19 infection in Africa: act collectively, and fast. Lancet. 2020;395(10227):841–2.
5 Haider N, Yavinsky A, Simons D, et al. Passengers’ destinations from China: low risk of novel coronavirus (2019-nCoV) transmission into Africa and South America. Epidemiol Infect. 2020;148:e41.
6 Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–11.
7 Gilbert M, Pullano G, Pinotti F, et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet. 2020;395(10227):871–7.
8 Tuite AR, Ng V, Rees E, et al. Estimation of the COVID-19 burden in Egypt through exported case detection. Lancet Infect Dis. 2020;20(8):894.
9 Negida A. Estimation of COVID-19 burden in Egypt. Lancet Infect Dis. 2020;20(8):895–6.
10 Wells CR, Sah P, Moghadas SM, et al. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proc Natl Acad Sci USA. 2020;117(13):7504–9.
11 World Health Organization. Coronavirus disease (COVID-19). Situation Report – 169. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200707-covid-19-sitrep-169.pdf?sfvrsn=c6c69c88_2 (accessed 7 July 2020).
12 Hopman J, Allegrenzi B, Mehtar S. Managing COVID-19 in low- and middle-income countries. JAMA. 2020;323(16):1549–50.
13 Lloyd-Sherlock P, Ebrahim S, Geffen L, McKee M. Bearing the brunt of COVID-19: older people in low and middle income countries. BMJ. 2020;368:m1052.
14 Peeri NC, Shrestha N, Rohman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49(3):717–26.